Other

Westfaelische Wilhelms-Universitaet Muenster

Clinuvel Pharmaceuticals Limited

Thomas A Luger

Philippe Wolgen

Karin Loser

The present invention is related to NDP-MSH or pharmaceutically acceptable salts thereof for therapeutic and/or prophylactic therapeutic treatment of inflammatory and/or neurodegenerative disorders of the CNS or multiple sclerosis. The present invention is further related to pharmaceutical compositions and a kit comprising NDP-MSH or pharmaceutically acceptable salts thereof.

NDP-MSH for treatment of inflammatory and/or neurodegenerative disorders of the central nervous system

The present invention relates to the use of compounds selected from the group consisting of Lys-(D)Pro-Thr, N-acyl Lys-(D)Pro-Thr, C-amide Lys-(D)Pro-Thr, and C-esters of Lys-(D)Pro-Thr; or a pharmaceutically acceptable salt of said compound for the treatment of inflammatory disorders. The invention also relates to the use of &#x3b1;MSH for inducing tolerance.

Inflammation inhibiting compounds

The present invention relates to the use of compounds selected from the group consisting of Lys-(D)Pro-Thr, N-acyl Lys-(D)Pro-Thr, C-amide Lys-(D)Pro-Thr, and C-esters of Lys-(D)Pro-Thr; or a pharmaceutically acceptable salt of said compound fort he treatment of inflammatory disorders. The invention also relates to the use of &#x3b1;MSH for inducing tolerance.

The present invention relates to the use of a compound of the formula Lys-X where X is a hydroxyl group, an amino group, alkoxy, Pro or Pro-Thr, or of a pharmaceutically acceptable salt thereof, for the treatment of inflammations. The invention also relates to the use of &#x3b1;MSH for inducing tolerance.

Growing community of inventors

Muenster, Germany

Thomas A Luger